Product Information

ZORYVE 0.3% CREAM is a brand product labeled by Arcutis Biotherapeutics, Inc., priced at $15.3798 per GM under NDC 80610013060. Its NADAC has been published 175 times since Apr 19, 2023.

FDA first approved this application on Jul 29, 2022.

The High Outlier badge above means this manufacturer's average price in the roflumilast market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

ZORYVE 0.3% CREAM

roflumilast
$15.3798per GM
High Outlier

Strength

3 mg/g

NDC

80610013060

Classification

Brand

Dosage Form

CREAM

Route

TOPICAL

Effective Date

8/19/2026

Active Ingredients

ROFLUMILAST

Approval Type

New Drug (NDA)

FDA Application

NDA215985

FDA Approved

7/29/2022

On Market Since

7/29/2022

Pharmacological Classes

Phosphodiesterase 4 Inhibitor
Phosphodiesterase 4 Inhibitors

Price Statistics

The NADAC for ZORYVE 0.3% CREAM has been published 175 times since Apr 19, 2023, and over the history we have for it it has risen 16.1%. The table below summarizes its recorded NADAC range and movement.

Current price$15.3798 per GM
All-time high$15.3897 (May 13, 2026)
All-time low$13.2416 (Apr 19, 2023)
52-week high$15.3897
52-week low$14.7978
Median price$14.2745
Average price$14.3575
Largest weekly change+4.0% (Nov 22, 2023)
Weeks tracked175
Tracking sinceApr 19, 2023

Price History

1W

+0.0%

1M

+0.0%

3M

+0.1%

6M

-0.1%

1Y

+3.9%

3Y

+16.1%

5Y

N/A

All

+16.1%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the roflumilast market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Frequently asked questions

What is the NADAC price of ZORYVE 0.3% CREAM?

The current National Average Drug Acquisition Cost (NADAC) for ZORYVE 0.3% CREAM, manufactured by Arcutis Biotherapeutics, Inc., is $15.3798 per GM (NDC 80610013060), effective Aug 19, 2026.

How has the price of ZORYVE 0.3% CREAM changed over time?

Over the history we have for it, the NADAC for ZORYVE 0.3% CREAM has risen 16.1%. It has been tracked across 175 weekly CMS publications since Apr 19, 2023.

What are the highest and lowest recorded NADAC prices for ZORYVE 0.3% CREAM?

Since Apr 19, 2023, the NADAC for ZORYVE 0.3% CREAM has ranged from a low of $13.2416 (Apr 19, 2023) to a high of $15.3897 (May 13, 2026), with a median of $14.2745 per GM.

Are there cheaper alternatives to ZORYVE 0.3% CREAM?

No other NADAC-published product currently shares the active ingredient and strength of ZORYVE 0.3% CREAM in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures ZORYVE 0.3% CREAM?

ZORYVE 0.3% CREAM (NDC 80610013060) is labeled by Arcutis Biotherapeutics, Inc., and CMS classifies it as a brand product.